Opthea Completes Recruitment in Phase 2a Clinical Trial of OPT-302 for Diabetic Macular Edema

7 January 2020 Melbourne, Australia – Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed patient recruitment into the Company’s Phase 2a trial evaluating the safety and efficacy of…

Read More

Home

News & opinion

Member Directory

Events